Host target therapeutics as a broad-spectrum antiviral for medically important positive-sense RNA viruses.
Applied/Translational Research
Singapore Health Biomedical Congress
Others
31 December 2022
To evaluate the antiviral properties of peruvoside, targeting broad-spectrum RNA viruses, including SARS-CoV-2. Peruvoside offers a scalable antiviral strategy with applications in RNA-virus-mediated diseases, complementing vaccine efforts.
Year Submitted: 2022
Published Date: 31 December 2022
Tags: Applied/Translational Research, Quantitative Research
About this Content
Aims
To evaluate the antiviral properties of peruvoside, targeting broad-spectrum RNA viruses, including SARS-CoV-2.
Background
Positive-sense RNA viruses like SARS-CoV-2, Dengue, and Zika cause global health challenges; antiviral therapeutics are limited.
Methods
Experimental lab studies and in vivo testing on mice, assessing viral replication inhibition via Golgi vesiculation pathways.
Results
Peruvoside demonstrated efficacy in broad-spectrum inhibition across RNA viruses with no cytotoxicity. Results suggested host-directed therapeutic potential.
Conclusion
Peruvoside offers a scalable antiviral strategy with applications in RNA-virus-mediated diseases, complementing vaccine efforts.
Lessons Learnt
Intracellular calcium flux is a key antiviral mechanism; leveraging host pathways can address multiple viral families.
Additional Information
SHBC 2022: Singapore Young Investigator Award (Basic Science) – Bronze Award
Keywords
Broad-Spectrum Antiviral, Host-Directed Therapies
Innovators' Details
Innovators' Details
Healthcare Cluster(s) | Others |
Organization(s) Involved | Yong Loo Lin School of Medicine, Agency for Science Technology and Research, Khonkaen University Thailand |
Platform(s) | Singapore Health Biomedical Congress |
Healthcare Professional Group(s) | Medical |
Applicable Specialty or Discipline | Infectious Diseases, Clinical Research |
Project Lead(s) | Justin Jang Hann Chu |
Project Member(s) | Kan Xing Wu |
Connect with this contributor!
Dr Thinesshwary Yogarajah - micthiy@nus.edu.sg
Project Attachment
C_52_NTU_SHBC_2022_Host_target_therapeutics_as_a_broad_spectrum_antiviral.pdf